(Q34229717)

31 July 2017

title

Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor, omapatrilat in healthy subjects (English)

1 reference

31 July 2017

1 reference

1 reference

Wei-Chi Liao

1

1 reference

31 July 2017

Ole Vesterqvist

2

1 reference

31 July 2017

Carol Delaney

3

1 reference

31 July 2017

Mohammed Jemal

4

1 reference

31 July 2017

Irene Ferreira

5

1 reference

31 July 2017

Neville Ford

6

1 reference

31 July 2017

Brian Swanson

7

1 reference

31 July 2017

Howard Uderman

8

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 October 2003

1 reference

British Journal of Clinical Pharmacology

31 July 2017

published in

1 reference

31 July 2017

volume

56

1 reference

31 July 2017

issue

4

1 reference

31 July 2017

page(s)

395-406

1 reference

Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension: results of the conduit hemodynamics of omapatrilat international research study

31 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884361

A review of vasopeptidase inhibitors: a new modality in the treatment of hypertension and chronic heart failure

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884361

Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884361

In-vitro and in-vivo inhibition of rat neutral endopeptidase and angiotensin converting enzyme with the vasopeptidase inhibitor gemopatrilat

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884361

Vasopeptidase inhibition: a new concept in blood pressure management

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884361

Bradykinin metabolism in the postinfarcted rat heart: role of ACE and neutral endopeptidase 24.11.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884361

Influence of captopril, propranolol, and verapamil on arterial pulse wave velocity and other cardiovascular parameters in healthy volunteers.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884361

Atrial natriuretic peptide-C receptor and membrane signalling in hypertension

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884361

Kinins and endothelial control of vascular smooth muscle

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884361

Enalapril (MK421) and its lysine analogue (MK521): a comparison of acute and chronic effects on blood pressure, renin-angiotensin system and sodium excretion in normal man.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884361

Effect of low dose infusion of atrial natriuretic peptide on renal function in man.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884361

Urodilatin (CDD/ANP-95-126) is not biologically inactivated by a peptidase from dog kidney cortex membranes in contrast to atrial natriuretic peptide/cardiodilatin (alpha-hANP/CDD-99-126)

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884361

Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884361

Inhibition of endopeptidase EC 24.11 in humans. Renal and endocrine effects

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884361

Dietary sodium and inhibition of neutral endopeptidase 24.11 in essential hypertension

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884361

Clinical Pharmacodynamic Studies with Cilazapril and a Combination of Cilazapril and Propranolol

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884361

Downregulation of glomerular and vascular atrial natriuretic factor receptor subtypes by angiotensin II.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884361

Role of nitric oxide-cGMP pathway in adrenomedullin-induced vasodilation in the rat.

6 July 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2125.2003.01888.X

Omapatrilat--the story of Overture and Octave

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884361

Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884361

Omapatrilat: neurohormonal and pharmacodynamic profile when administered with furosemide

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884361

Omapatrilat versus lisinopril: efficacy and neurohormonal profile in salt-sensitive hypertensive patients

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884361

Potentiation of the renal responses to bradykinin by inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in anesthetized dogs.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884361

Natriuretic response to neutral endopeptidase inhibition is blunted by enalapril in healthy men

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884361

Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells

28 October 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2125.2003.01888.X

Effects of SCH 34826, an orally active inhibitor of atrial natriuretic peptide degradation, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2125.2003.01888.X

Low dose infusion of atrial natriuretic peptide causes salt and water excretion in normal man

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2125.2003.01888.X

Marked difference between angiotensin-converting enzyme and neutral endopeptidase inhibition in vivo by a dual inhibitor of both enzymes

21 January 2018

1 reference

12 December 2020

Antihypertensive and natriuretic effects of CGS 30440, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase 24.11

1 reference

12 December 2020

Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans

1 reference

12 December 2020

Atrial Natriuretic Peptide: Regulator of Chronic Arterial Blood Pressure

1 reference

12 December 2020

Characterization of neutral endopeptidase in vascular cells, modulation of vasoactive peptide levels

1 reference

12 December 2020

Human kidney "enkephalinase", a neutral metalloendopeptidase that cleaves active peptides

1 reference

12 December 2020

Isolation and structural analysis of "urodilatin", a new peptide of the cardiodilatin-(ANP)-family, extracted from human urine

1 reference

12 December 2020

Omapatrilat in patients with hepatic cirrhosis. Pharmacodynamics and pharmacokinetics

1 reference

12 December 2020

Combination of high-performance liquid chromatography and radioimmunoassay for the measurement of urodilatin and alpha-hANP in the urine of healthy males

1 reference

12 December 2020

Characterization of a dual inhibitor of angiotensin I-converting enzyme and neutral endopeptidase

1 reference

12 December 2020

Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II

1 reference

12 December 2020

Quantitative determination of BMS186716, a thiol compound, in dog plasma by high-performance liquid chromatography-positive ion electrospray mass spectrometry after formation of the methyl acrylate adduct

1 reference

12 December 2020

Acute renal effects of neutral endopeptidase inhibition in humans

1 reference

12 December 2020

Rat vascular tissue contains a neutral endopeptidase capable of degrading atrial natriuretic peptide

1 reference

12 December 2020

Effects of age and gender on the pharmacodynamics of omapatrilat in healthy volunteers

1 reference

12 December 2020

Pharmacokinetics of ANF and urodilatin during cANF receptor blockade and neutral endopeptidase inhibition

1 reference

12 December 2020

Effects of omapatrilat in low, normal, and high renin experimental hypertension

1 reference

12 December 2020

10.1046/J.1365-2125.2003.01888.X

Identifiers

DOI

1 reference

31 July 2017

1 reference

31 July 2017

1 reference